INSIGHTS ON PHARMACEUTICAL LOGISTICS

• Optimizing End-To-End Contract Analytical Support For Cell And Gene Therapies

  The development and production of CGTs presents unparalleled complexities. Learn how a partner with robust end-to-end services can help you overcome challenges at every step of the drug lifecycle.

• Friendshoring: A Strategic Shift In Pharma Supply Chains

  To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

• Risk Mitigation For Late-Stage Clinical Assets

  Leveraging the competence and capabilities of the CDMO to bring forth innovative, flexible solutions to safeguard supply chains for their clients and, ultimately, for patients is crucial to strategic partnering.

• Shedding Light On Photo-Stability Forced Degradation

  Ensure the stability and safety of your drug products by utilizing comprehensive forced degradation and photo-stability testing, guided by ICH and FDA standards, to identify degradation pathways and assess light exposure risks.

• The Crucial Role Of Cleaning In Effective VPHP Decontamination For Isolators

  12/27/2024

  Effective isolator cleaning is crucial for vapor phase hydrogen peroxide (VPHP) decontamination. Proper tools, techniques, and training ensure sterility, and regulatory compliance.

• Windsor Framework: What Is It?

  9/2/2025

  Learn about the Windsor Framework and how it addresses the challenges of medicine supply chains between the UK and the EU, creating stability and certainty in the post-Brexit world.

• Stick-Pack Benefits For Pharmaceuticals And Nutraceuticals

  10/24/2024

  Explore the key advantages of stick-pack formats for pharmaceuticals and nutraceuticals, from enhanced product safety and cost-efficiency to improved compliance and marketability.

• Fast-Track Innovation, Address CMC Challenges In Expedited Pathways

  1/26/2026

  Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

• Integrated Single-Site CDMO Model

  3/16/2026

  A single‑site model reduces handoff risks, speeds timelines, strengthens quality oversight, and unifies development and manufacturing to improve reliability and execution efficiency.